Gerald Verhaegh

List of Publications by Year
in descending order

82 papers	5,354 citations	147566 31 h-index	82410 72 g-index
82 all docs	82 docs citations	82 times ranked	7239 citing authors

#	Article	IF	Citations
1	Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Nonâ€“muscle-invasive Bladder Cancer. European Urology Oncology, 2022, 5, 70-83.	2.6	5
2	Delivery of antisense oligonucleotides for spliceâ€correction of androgen receptor preâ€mRNA in castrationâ€resistant prostate cancer models using cellâ€penetrating peptides. Prostate, 2022, 82, 657-665.	1.2	7
3	The Identification of Small Molecule Inhibitors That Reduce Invasion and Metastasis of Aggressive Cancers. International Journal of Molecular Sciences, 2021, 22, 1688.	1.8	1
4	Predictive and prognostic biomarker identification in a large cohort of androgen receptor-positive salivary duct carcinoma patients scheduled for combined androgen blockade.. Journal of Clinical Oncology, 2021, 39, 6071-6071.	0.8	0
5	Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castrationâ€resistant prostate cancer undergoing firstâ€line abiraterone acetate and prednisone treatment. Molecular Oncology, 2021, 15, 2453-2465.	2.1	9
6	Androgen receptor signalling confers clonogenic and migratory advantages in urothelial cell carcinoma of the bladder. Molecular Oncology, 2021, 15, 1882-1900.	2.1	5
7	Upregulation of miR-3195, miR-3687 and miR-4417 is associated with castration-resistant prostate cancer. World Journal of Urology, 2021, 39, 3789-3797.	1.2	14
8	Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade. Cancers, 2021, 13, 3527.	1.7	10
9	Partial Adrenalectomy Carries a Considerable Risk of Incomplete Cure in Primary Aldosteronism. Journal of Urology, 2021, 206, 219-228.	0.2	4
10	Molecular Phenotyping of AR Signaling for Predicting Targeted Therapy in Castration Resistant Prostate Cancer. Frontiers in Oncology, 2021, 11, 721659.	1.3	3
11	RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 6279.	1.7	5
12	Clinical utility of emerging biomarkers in prostate cancer liquid biopsies. Expert Review of Molecular Diagnostics, 2020, 20, 219-230.	1.5	36
13	Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients. International Journal of Cancer, 2020, 146, 3196-3206.	2.3	28
14	Prognostic value of PSMA, c-MET and E-cadherin in salivary duct carcinoma. Oral Oncology, 2020, 110, 105018.	0.8	4
15	Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review. Cancer Treatment Reviews, 2020, 89, 102069.	3.4	32
16	Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study. Clinical Chemistry, 2020, 66, 842-851.	1.5	25
17	⁶⁸Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study. Theranostics, 2020, 10, 2273-2283.	4.6	45
18	Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis. Oncogene, 2019, 38, 3696-3709.	2.6	26

#	Article	IF	Citations
19	Adjuvant androgen deprivation therapy for poor-risk, androgen receptorâ€“positive salivary duct carcinoma. European Journal of Cancer, 2019, 110, 62-70.	1.3	46
20	The importance of targeting intracrinology in prostate cancer management. World Journal of Urology, 2019, 37, 751-757.	1.2	2
21	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. British Journal of Cancer, 2018, 118, 266-276.	2.9	12
22	<scp>LINC</scp>00857 expression predicts and mediates the response to platinumâ€based chemotherapy in muscleâ€invasive bladder cancer. Cancer Medicine, 2018, 7, 3342-3350.	1.3	31
23	Identification of an enhancer region within the TP63/LEPREL1 locus containing genetic variants associated with bladder cancer risk. Cellular Oncology (Dordrecht), 2018, 41, 555-568.	2.1	11
24	miRNA-520f Reverses Epithelial-to-Mesenchymal Transition by TargetingADAM9andTGFBR2. Cancer Research, 2017, 77, 2008-2017.	0.4	55
25	The Non-Coding Transcriptome of Prostate Cancer: Implications for Clinical Practice. Molecular Diagnosis and Therapy, 2017, 21, 385-400.	1.6	18
26	Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. Oncotarget, 2017, 8, 50804-50813.	0.8	29
27	Adjuvant androgen deprivation therapy for high-risk androgen receptor-positive salivary duct carcinoma. Annals of Oncology, 2017, 28, v373-v374.	0.6	0
28	A short-term intervention with selenium affects expression of genes implicated in the epithelial-to-mesenchymal transition in the prostate. Oncotarget, 2017, 8, 10565-10579.	0.8	26
29	Identification of long non-coding RNAs that stimulate cell survival in bladder cancer. Oncotarget, 2017, 8, 34442-34452.	0.8	12
30	Independent Replication of Published Germline Polymorphisms Associated with Urinary Bladder Cancer Prognosis and Treatment Response. Bladder Cancer, 2016, 2, 77-89.	0.2	24
31	<scp>TRPV</scp>4 channels in the human urogenital tract play a role in cell junction formation and epithelial barrier. Acta Physiologica, 2016, 218, 38-48.	1.8	22
32	Abstract 3768: Targeting of epithelial-to-mesenchyme transition by a novel small molecule inhibitor attenuates prostate and breast cancer invasiveness and bone metastases. , 2016, , .		0
33	The role of HOXC6 in prostate cancer development. Prostate, 2015, 75, 1868-1876.	1.2	43
34	The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 202.e19-202.e28.	0.8	8
35	Dutasteride and Enzalutamide Synergistically Suppress Prostate Tumor Cell Proliferation. Journal of Urology, 2015, 193, 1023-1029.	0.2	15
36	Noncoding RNAs as Novel Biomarkers in Prostate Cancer. BioMed Research International, 2014, 2014, 1-17.	0.9	83

#	Article	IF	Citations
37	Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy. Prostate International, 2014, 2, 105-113.	1.2	27
38	MP31-13 THE EXPRESSION AND FUNCTION OF FAM110A IN HUMAN PROSTATE CANCER. Journal of Urology, 2014, 191, .	0.2	0
39	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology, 2014, 66, 489-499.	0.9	195
40	Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer. Human Molecular Genetics, 2014, 23, 5545-5557.	1.4	46
41	Prognostic Relevance of Urinary Bladder Cancer Susceptibility Loci. PLoS ONE, 2014, 9, e89164.	1.1	20
42	MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene, 2013, 32, 277-285.	2.6	198
43	Urinary Bladder Cancer Susceptibility Markers. What Do We Know about Functional Mechanisms?. International Journal of Molecular Sciences, 2013, 14, 12346-12366.	1.8	30
44	226 THE RATIONALE OF COMBINATION THERAPY TARGETING INTRATUMORAL STEROIDOGENESIS IN CASTRATION RESISTANT PROSTATE CANCER (CRPC). Journal of Urology, 2012, 187, .	0.2	0
45	Aldo-keto Reductase Family 1 Member C3 (AKR1C3) Is a Biomarker and Therapeutic Target for Castration-Resistant Prostate Cancer. Molecular Medicine, 2012, 18, 1449-1455.	1.9	70
46	Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castrationâ€resistant prostate cancer. Prostate, 2012, 72, 789-802.	1.2	30
47	DCâ€SCRIPT: AR and VDR regulator lost upon transformation of prostate epithelial cells. Prostate, 2012, 72, 1708-1717.	1.2	17
48	Abstract 1112: Identification of microRNA-based therapeutic candidates using a unique lentiviral microRNA overexpression library. , 2012, , .		0
49	Arachidonic Acid Pathway Members PLA2G7, HPGD, EPHX2, and CYP4F8 Identified as Putative Novel Therapeutic Targets in Prostate Cancer. American Journal of Pathology, 2011, 178, 525-536.	1.9	102
50	Prevalence of human xenotropic murine leukemia virusâ€related gammaretrovirus (XMRV) in dutch prostate cancer patients. Prostate, 2011, 71, 415-420.	1.2	44
51	European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Human Molecular Genetics, 2011, 20, 4268-4281.	1.4	134
52	Prevalence of xenotropic murine leukaemia virus-related virus in patients with chronic fatigue syndrome in the Netherlands: retrospective analysis of samples from an established cohort. BMJ: British Medical Journal, 2010, 340, c1018-c1018.	2.4	143
53	Predictive value of PCA3 in urinary sediments in determining clinicoâ€pathological characteristics of prostate cancer. Prostate, 2010, 70, 10-16.	1.2	144
54	Differential expression of PCA3 and its overlapping PRUNE2 transcript in prostate cancer. Prostate, 2010, 70, 70-78.	1.2	47

#	Article	IF	Citations
55	A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nature Genetics, 2010, 42, 415-419.	9.4	169
56	Reply to the letter to the editor: â€œDifferential expression of PCA3 and BMCC1 in Prostate Cancer,â€•by Lavin M.F., Clarke R. and R.A. Gardiner. Prostate, 2009, 69, 1715-1715.	1.2	0
57	Polymorphisms in the H19 Gene and the Risk of Bladder Cancer. European Urology, 2008, 54, 1118-1126.	0.9	127
58	DETECTION OF TMPRSS2-ERG FUSION TRANSCRIPTS AND PCA3 IN URINARY SEDIMENTS MAY IMPROVE DIAGNOSIS OF PROSTATE CANCER. Journal of Urology, 2008, 179, 685-685.	0.2	1
59	Detection of TMPRSS2-ERG Fusion Transcripts and Prostate Cancer Antigen 3 in Urinary Sediments May Improve Diagnosis of Prostate Cancer. Clinical Cancer Research, 2007, 13, 5103-5108.	3.2	312
60	TMPRSS2 Fusions with Oncogenic ETS Factors in Prostate Cancer Involve Unbalanced Genomic Rearrangements and Are Associated with HDAC1 and Epigenetic Reprogramming. Cancer Research, 2006, 66, 10242-10246.	0.4	209
61	Polymorphisms in the E-cadherin (CDH1) gene promoter and the risk of bladder cancer. European Journal of Cancer, 2006, 42, 3219-3227.	1.3	22
62	EFFECT OF HYPERTHERMIA ON THE CYTOTOXICITY OF 4 CHEMOTHERAPEUTIC AGENTS CURRENTLY USED FOR THE TREATMENT OF TRANSITIONAL CELL CARCINOMA OF THE BLADDER: AN IN VITRO STUDY. Journal of Urology, 2005, 173, 1375-1380.	0.2	92
63	Applicability of biomarkers in the early diagnosis of prostate cancer. Expert Review of Molecular Diagnostics, 2004, 4, 513-526.	1.5	47
64	Strict regulation of CAIXG250/MN by HIF-1Î± in clear cell renal cell carcinoma. Oncogene, 2004, 23, 5624-5631.	2.6	177
65	The Effect of Hyperthermia on Mitomycin-C Induced Cytotoxicity in Four Human Bladder Cancer Cell Lines. European Urology, 2004, 46, 670-674.	0.9	40
66	New targets for therapy in prostate cancer: differential display code 3 (DD3PCA3), a highly prostate cancerâ€“specific gene. Urology, 2003, 62, 34-43.	0.5	133
67	Î”N-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene, 2002, 21, 6722-6728.	2.6	229
68	DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Research, 2002, 62, 2695-8.	0.4	484
69	A novel method for the determination of basal gene expression of tissue-specific promoters: An analysis of prostate-specific promoters. Cancer Gene Therapy, 2001, 8, 927-935.	2.2	23
70	Isolation and Characterization of the Promoter of the Human Prostate Cancer-specific DD3 Gene. Journal of Biological Chemistry, 2000, 275, 37496-37503.	1.6	34
71	Immortalization and characterization of Nijmegen Breakage Syndrome fibroblasts. Mutation Research DNA Repair, 1999, 434, 17-27.	3.8	98
72	Metal ions as regulators of the conformation and function of the tumour suppressor protein p53: implications for carcinogenesis. Proceedings of the Nutrition Society, 1999, 58, 565-571.	0.4	30

#	Article	IF	Citations
73	DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Research, 1999, 59, 5975-9.	0.4	803
74	Modulation of p53 protein conformation and DNA-binding activity by intracellular chelation of zinc. , 1998, 21, 205-214.		98
75	Regulation of p53 by Metal Ions and by Antioxidants: Dithiocarbamate Down-Regulates p53 DNA-Binding Activity by Increasing the Intracellular Level of Copper. Molecular and Cellular Biology, 1997, 17, 5699-5706.	1.1	169
76	The defect in the AT-like hamster cell mutants is complemented by mouse chromosome 9 but not by any of the human chromosomes. Mutation Research DNA Repair, 1996, 364, 91-102.	3.8	10
77	A novel type of X-ray-sensitive Chinese hamster cell mutant with radioresistant DNA synthesis and hampered DNA double-strand break repair. Mutation Research DNA Repair, 1995, 337, 119-129.	3.8	27
78	Studies on phenotypic complementation of ataxia-telangiectasia cells by chromosome transfer. American Journal of Human Genetics, 1995, 56, 438-43.	2.6	6
79	A gene that regulates DNA replication in response to DNA damage is located on human chromosome 4q. American Journal of Human Genetics, 1995, 57, 1095-103.	2.6	17
80	Cellular characteristics of Chinese hamster cell mutants resembling ataxia telangiectasia cells. Mutation Research DNA Repair, 1993, 294, 207-214.	3.8	13
81	Co-dominance of radioresistant DNA synthesis in a group of AT-like Chinese hamster cell mutants. Cytogenetic and Genome Research, 1993, 63, 176-180.	0.6	20
82	Differential expression of vimentin in rat prostatic tumors. Biochemical and Biophysical Research Communications, 1992, 182, 1254-1259.	1.0	21